What was the overall market valuation for parathyroid disorders in 2024?

The overall market valuation for parathyroid disorders was $417.9 Million in 2024. Read More

What is the projected market valuation for parathyroid disorders by 2035?

The projected market valuation for parathyroid disorders is $800.0 Million by 2035. Read More

What is the expected CAGR for the US parathyroid disorders market during the forecast period 2025 - 2035?

The expected CAGR for the US parathyroid disorders market during the forecast period 2025 - 2035 is 6.08%. Read More

Which companies are considered key players in the parathyroid disorders market?

Key players in the parathyroid disorders market include Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Pfizer Inc, Sanofi S.A., Teva Pharmaceutical Industries Ltd, and AbbVie Inc. Read More

What are the market segments for parathyroid disorders based on the type of disorder?

The market segments based on the type of disorder include Primary Hyperparathyroidism ($200.0 - $400.0 Million), Secondary Hyperparathyroidism ($150.0 - $300.0 Million), and Tertiary Hyperparathyroidism ($67.9 - $100.0 Million). Read More

What treatment types are available for parathyroid disorders and their market valuations?

Available treatment types include Medications ($100.0 - $200.0 Million), Surgery ($150.0 - $300.0 Million), Radiation Therapy ($50.0 - $100.0 Million), and Observation ($117.9 - $200.0 Million). Read More

What diagnostic methods are utilized in the parathyroid disorders market?

Diagnostic methods include Blood Tests ($150.0 - $300.0 Million), Imaging Tests ($200.0 - $400.0 Million), and Biopsies ($67.9 - $100.0 Million). Read More

How is the patient age group segmented in the parathyroid disorders market?

The patient age group segmentation includes Children ($50.0 - $100.0 Million), Adults ($250.0 - $500.0 Million), and Elderly ($117.9 - $200.0 Million). Read More

What does the market outlook for parathyroid disorders suggest for the future?

The market outlook for parathyroid disorders suggests a robust growth trajectory, with a projected valuation of $800.0 Million by 2035. Read More

How do the treatment and diagnosis segments compare in terms of market valuation?

The treatment segment, particularly Surgery, is projected to have a higher valuation ($150.0 - $300.0 Million) compared to the diagnosis segment, with Imaging Tests valued at $200.0 - $400.0 Million. Read More

US Parathyroid Disorders Market

US Parathyroid Disorders Market Research Report By Type of Disorder (Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism), By Treatment Type (Medications, Surgery, Radiation Therapy, Observation), By Diagnosis Method (Blood Tests, Imaging Tests, Biopsies) and By Patient Age Group (Children, Adults, Elderly) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.08%

2024 Market Size

$ 417.9 Million

2035 Market Size

$ 800 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/18456-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type of Disorder (USD Million)
  1. 4.1.1 Primary Hyperparathyroidism
  2. 4.1.2 Secondary Hyperparathyroidism
  3. 4.1.3 Tertiary Hyperparathyroidism
2. 4.2 Life Sciences, BY Treatment Type (USD Million)
  1. 4.2.1 Medications
  2. 4.2.2 Surgery
  3. 4.2.3 Radiation Therapy
  4. 4.2.4 Observation
3. 4.3 Life Sciences, BY Diagnosis Method (USD Million)
  1. 4.3.1 Blood Tests
  2. 4.3.2 Imaging Tests
  3. 4.3.3 Biopsies
4. 4.4 Life Sciences, BY Patient Age Group (USD Million)
  1. 4.4.1 Children
  2. 4.4.2 Adults
  3. 4.4.3 Elderly
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi S.A. (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE OF DISORDER
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE OF DISORDER, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE OF DISORDER, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY PATIENT AGE GROUP, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF DISORDER, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Parathyroid Disorders Market Segmentation

US Parathyroid Disorders Market By Type of Disorder (USD Million, 2025-2035)

Primary Hyperparathyroidism
Secondary Hyperparathyroidism
Tertiary Hyperparathyroidism

US Parathyroid Disorders Market By Treatment Type (USD Million, 2025-2035)

Medications
Surgery
Radiation Therapy
Observation

US Parathyroid Disorders Market By Diagnosis Method (USD Million, 2025-2035)

Blood Tests
Imaging Tests
Biopsies

US Parathyroid Disorders Market By Patient Age Group (USD Million, 2025-2035)

Children
Adults
Elderly

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”